333 related articles for article (PubMed ID: 29172978)
1. Application of the FDA Biosimilar Extrapolation Framework to Make Off-Label Determinations.
Li E; Lobaina E
J Manag Care Spec Pharm; 2017 Dec; 23(12):1227-1232. PubMed ID: 29172978
[TBL] [Abstract][Full Text] [Related]
2. Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness.
Dutcher SK; Fazio-Eynullayeva E; Eworuke E; Carruth A; Dee EC; Blum MD; Nguyen MD; Toh S; Panozzo CA; Lyons JG
Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):786-795. PubMed ID: 31828887
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?
Hung A; Vu Q; Mostovoy L
J Manag Care Spec Pharm; 2017 Dec; 23(12):1234-1244. PubMed ID: 29172975
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
Schellekens H; Lietzan E; Faccin F; Venema J
Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
[TBL] [Abstract][Full Text] [Related]
5. Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients.
Dean EB; Johnson P; Bond AM
JAMA Netw Open; 2021 Jan; 4(1):e2034776. PubMed ID: 33502485
[TBL] [Abstract][Full Text] [Related]
6. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019.
Liu A; Xuan A; Socal M; Anderson G; Anderson KE
J Manag Care Spec Pharm; 2024 Jan; 30(1):15-21. PubMed ID: 38153867
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
Ben-Horin S; Vande Casteele N; Schreiber S; Lakatos PL
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia.
Douglas AG; Schwab P; Lane D; Kennedy K; Slabaugh SL; Bowe A
J Manag Care Spec Pharm; 2017 Dec; 23(12):1221-1226. PubMed ID: 29172983
[TBL] [Abstract][Full Text] [Related]
9. Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb.
Bhat S; Altajar S; Shankar D; Zahorian T; Robert R; Qazi T; Shah B; Farraye FA
J Manag Care Spec Pharm; 2020 Apr; 26(4):410-416. PubMed ID: 32223602
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
[TBL] [Abstract][Full Text] [Related]
12. Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018.
Qian J
J Manag Care Spec Pharm; 2021 May; 27(5):660-666. PubMed ID: 33908273
[No Abstract] [Full Text] [Related]
13. [Opportunities and challenges of extrapolation for biosimilars].
Weise M; Wolff-Holz E
Z Gastroenterol; 2016 Nov; 54(11):1211-1216. PubMed ID: 27711947
[TBL] [Abstract][Full Text] [Related]
14. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
Mansell K; Bhimji H; Eurich D; Mansell H
BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
[TBL] [Abstract][Full Text] [Related]
15. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges.
Chapman K; Adjei A; Baldrick P; da Silva A; De Smet K; DiCicco R; Hong SS; Jones D; Leach MW; McBlane J; Ragan I; Reddy P; Stewart DI; Suitters A; Sims J
MAbs; 2016; 8(3):427-35. PubMed ID: 26854177
[TBL] [Abstract][Full Text] [Related]
16. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System.
Bhardwaja B; Klocke S; Ekinci E; Jackson A; Kono S; Olson KL
BioDrugs; 2022 Jan; 36(1):1-11. PubMed ID: 34817847
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars: From Extrapolation into Off Label Use.
Zhao S; Nair JR; Moots RJ
Curr Pharm Des; 2017; 23(44):6746-6751. PubMed ID: 29189127
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage.
Karaca-Mandic P; Chang J; Go R; Schondelmeyer S; Weisdorf D; Jeffery MM
Health Aff (Millwood); 2019 Nov; 38(11):1887-1892. PubMed ID: 31682491
[TBL] [Abstract][Full Text] [Related]
19. Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim.
Socal MP; Anderson KE; Sen A; Bai G; Anderson GF
Value Health; 2020 Apr; 23(4):481-486. PubMed ID: 32327165
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
